SIRS-Lab announced the closing of a follow up financing round led by Affentranger Associates SA alongside with bm|t beteiligungsmanagement thüringen gmbh. This new round aims at a rapid ramp up of SIRS-Lab’s sales and marketing organization.
Sepsis is the 2nd cause of death in hospitals after cardio-vascular disease with more than 2 millions cases per year. Limited viable and fast diagnostic methods are currently available. SIRS-Lab, a leading molecular diagnostic company in the field of life-threatening infections, obtained further funding to expand and further commercialize its breakthrough sepsis diagnostic suite composed of two unique products VYOO and SIQNATURE.
“With the strong backing of our existing investor group, we can carry forward the current strong momentum at SIRS-Lab” says bm|t’s CEO Dr. Guido Bohnenkamp. “The unique diagnostics developed by SIRS-Lab address the unmet medical need of early sepsis detection and are getting strong traction in the market; the latest financing round will allow the company to invest in the commercial organization to accelerate this adoption process across the world.” adds Nicolas Fulpius, Chairman of the board of SIRS-Lab and Partner at Affentranger Associates.
VYOO – an IQ Innovation award winning test – is a cutting-edge pathogen detection test that enables physicians to determine the causative agent of a deadly infection much earlier and more reliably than currently possible. SIQNATURE was recently presented to the scientific community at the “International Shock Society” congress in Cologne. The breakthrough immune monitoring test allows early detection of sepsis and monitoring of patients at risk. VYOO is available for purchase since December 2007; SIQNATURE will be marketed starting in Q4 2008.
Sepsis is a life-threatening systemic infection and one of the main causes of death in hospitals worldwide. Per year, around 2 Mio people suffer from the disease in industrial countries alone. 50% of the patients die. Sepsis further consumes a major part of health care resources. Molecular diagnostic solutions meet the currently unmet medical needs of fast and reliable identification of sepsis.
Located in Jena, Germany, SIRS-Lab is a molecular diagnostic company developing unique and innovative products to identify and monitor life-threatening infections as sepsis, one of the major cause of death in hospitals. Created as a spin-off of the University Klinik of Jena, SIRS-Lab was founded in 2000 by S. Russwurm, K. Reinhart, E. Straube, and H.-P. Saluz and currently employs 50 people.
About Affentranger Associates SA
Incorporated in 2002, Affentranger Associates is a Switzerland based business platform focused on the theme of value creation and active management. As principal investor, the company has the ambition to achieve sustainable long-term returns by investing a combination of management and capital in high-growth potential companies. Affentranger Associates has offices in Geneva and Zurich.
Dr. Stefan Russwurm — CEO
+49 (0) 3641 508–430
Affentranger Associates SA
+41 228 180–180